97 related articles for article (PubMed ID: 2255397)
1. Chronic effects of the selective serotoninergic neurotoxin, methylenedioxyamphetamine, upon cerebral function.
McBean DE; Sharkey J; Ritchie IM; Kelly PA
Neuroscience; 1990; 38(1):271-5. PubMed ID: 2255397
[TBL] [Abstract][Full Text] [Related]
2. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy").
Sharkey J; McBean DE; Kelly PA
Psychopharmacology (Berl); 1991; 105(1):113-8. PubMed ID: 1684057
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cerebrovascular responsiveness to hypercapnia following depletion of central serotonergic terminals.
Kelly PA; Ritchie IM; McBean DE; Sharkey J; Olverman HJ
J Cereb Blood Flow Metab; 1995 Jul; 15(4):706-13. PubMed ID: 7790420
[TBL] [Abstract][Full Text] [Related]
4. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography.
Battaglia G; Sharkey J; Kuhar MJ; de Souza EB
Synapse; 1991 Aug; 8(4):249-60. PubMed ID: 1681594
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
[TBL] [Abstract][Full Text] [Related]
6. Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomography ligand?
Scheffel U; Ricaurte GA
Brain Res; 1990 Sep; 527(1):89-95. PubMed ID: 1980843
[TBL] [Abstract][Full Text] [Related]
7. Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives.
Mamounas LA; Mullen CA; O'Hearn E; Molliver ME
J Comp Neurol; 1991 Dec; 314(3):558-86. PubMed ID: 1814975
[TBL] [Abstract][Full Text] [Related]
8. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography.
Appel NM; Mitchell WM; Contrera JF; De Souza EB
Synapse; 1990; 6(1):33-44. PubMed ID: 2144664
[TBL] [Abstract][Full Text] [Related]
9. Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat.
Wilkerson G; London ED
Neuropharmacology; 1989 Oct; 28(10):1129-38. PubMed ID: 2572994
[TBL] [Abstract][Full Text] [Related]
10. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
Nash JF; Arora RC; Schreiber MA; Meltzer HY
Biochem Pharmacol; 1991 Jan; 41(1):79-84. PubMed ID: 1702633
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a possible role for serotonergic systems in the control of cerebral blood flow.
McBean DE; Sharkey J; Ritchie IM; Kelly PA
Brain Res; 1990 Dec; 537(1-2):307-10. PubMed ID: 2128199
[TBL] [Abstract][Full Text] [Related]
12. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals.
Ricaurte G; Bryan G; Strauss L; Seiden L; Schuster C
Science; 1985 Sep; 229(4717):986-8. PubMed ID: 4023719
[TBL] [Abstract][Full Text] [Related]
13. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Colado MI; Williams JL; Green AR
Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
[TBL] [Abstract][Full Text] [Related]
14. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.
Ricaurte GA; Martello AL; Katz JL; Martello MB
J Pharmacol Exp Ther; 1992 May; 261(2):616-22. PubMed ID: 1374470
[TBL] [Abstract][Full Text] [Related]
15. Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. I. Effects of electrolytic or neurotoxic lesions of the dorsal and/or median raphé nucleus.
Cudennec A; Duverger D; Nishikawa T; McRae-Degueurce A; MacKenzie ET; Scatton B
Brain Res; 1988 Mar; 444(2):214-26. PubMed ID: 3359293
[TBL] [Abstract][Full Text] [Related]
16. Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. II. Effects of electrical stimulation of the rostral raphé nuclei.
Cudennec A; Duverger D; Serrano A; Scatton B; MacKenzie ET
Brain Res; 1988 Mar; 444(2):227-46. PubMed ID: 3359294
[TBL] [Abstract][Full Text] [Related]
17. Differential patterns of local cerebral glucose utilization in response to 5-hydroxytryptamine agonists.
Kelly PA; Davis CJ; Goodwin GM
Neuroscience; 1988 Jun; 25(3):907-15. PubMed ID: 2970017
[TBL] [Abstract][Full Text] [Related]
18. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies.
Schechter LE; Bolaños FJ; Gozlan H; Lanfumey L; Haj-Dahmane S; Laporte AM; Fattaccini CM; Hamon M
J Pharmacol Exp Ther; 1990 Dec; 255(3):1335-47. PubMed ID: 1702155
[TBL] [Abstract][Full Text] [Related]
19. Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain.
De Souza EB; Kuyatt BL
Synapse; 1987; 1(5):488-96. PubMed ID: 2975068
[TBL] [Abstract][Full Text] [Related]
20. Sequelae of parenteral domoic acid administration in rats: comparison of effects on different metabolic markers in brain.
Appel NM; Rapoport SI; O'Callaghan JP; Bell JM; Freed LM
Brain Res; 1997 Apr; 754(1-2):55-64. PubMed ID: 9134959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
